Uncategorized
EyePoint plummets on pivotal data for main drug

Though its drug missed the main goal of a wet AMD study, EyePoint, as well as analysts, still see a path toward approval. Investors may be harder to win over, however.
Though its drug missed the main goal of a wet AMD study, EyePoint, as well as analysts, still see a path toward approval. Investors may be harder to win over, however.